CAS 1009119-64-5

Daclatasvir

Description:

Daclatasvir is an antiviral medication primarily used in the treatment of hepatitis C virus (HCV) infections. It functions as a direct-acting antiviral agent, specifically an NS5A inhibitor, which interferes with the viral replication process. Daclatasvir is characterized by its high potency against various HCV genotypes and is often used in combination with other antiviral drugs to enhance efficacy and reduce the risk of resistance. The substance is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Its chemical structure includes a complex arrangement of heterocycles, contributing to its mechanism of action and therapeutic effectiveness. Daclatasvir is generally well-tolerated, with a side effect profile that may include fatigue, headache, and nausea, though serious adverse effects are rare. As with any antiviral therapy, monitoring for drug interactions and adherence to treatment regimens is crucial for optimal outcomes in patients undergoing hepatitis C treatment.

Formula: C₄₀H₅₀N₈O₆

InChI: InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1

InChI key: InChIKey=FKRSSPOQAMALKA-CUPIEXAXSA-N

SMILES: C([C@@H](NC(OC)=O)C(C)C)(=O)N1[C@@H](CCC1)C=2NC(=CN2)C3=CC=C(C=C3)C4=CC=C(C=C4)C=5NC(=NC5)[C@H]6N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC6

Synonyms:

• Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, dimethyl ester
• Carbamic acid, N,N′-[[1,1′-biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C′-dimethyl ester
• Daclatasvir
• Daclavirocyrl
• Daklanork
• Ebp 883
• Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]c arbamate
• dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
• BMS 790052
• Daclatasvir, >=98%
• Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))
• N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester
• Daklinza
• Daclatasvir-d16
• diMethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)
• DiMethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-iMidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-Methyl-1-oxobutane-2, 1-diyl)dicarbaMate (Related Reference)
• Dacaltasvir
• N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester Daclatasvir BMS 790052
• BMS-790052(Daclatasvir)
• Dhaka He Wei
• Daclatasvir/EBP883

Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester

CAS: 1009119-64-5

Formula: C₄₀H₅₀N₈O₆

Purity: 98%

Color and Shape: Solid

Molecular weight: 738.8750

Ref: IN-DA00036K

Daclatasvir-d16

CAS: 1009119-64-5

Formula: C₄₀H₃₄D₁₆N₈O₆

Color and Shape: Yellow Solid

Molecular weight: 754.99

Ref: 4Z-D-145002

Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)Carbamate

CAS: 1009119-64-5

Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)Carbamate

Purity: 98%

Molecular weight: 738.88g/mol

Ref: 54-OR1026411

Daclatasvir

CAS: 1009119-64-5

Daclatasvir

Purity: ≥98%

Molecular weight: 738.88g/mol

Ref: 54-BUP14405

Daclatasvir

CAS: 1009119-64-5

Daclatasvir (EBP 883/BMS-790052) is a potent HCV NS5A inhibitor with EC50 9-50 pM across various genotypes. Phase 3.

Formula: C₄₀H₅₀N₈O₆

Purity: 99.81%

Color and Shape: Solid

Molecular weight: 738.88

Ref: TM-T6229

Daclatasvir

Controlled Product

CAS: 1009119-64-5

Applications Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
References Gao, M., et al.: Nature, 465(7294), 96 (2010); Bell, T. W., Chem. Med. Chem., 5(10), 1663 (2010);

Formula: C₄₀H₅₀N₈O₆

Color and Shape: Neat

Molecular weight: 738.88

Ref: TR-D101500

Daclatasvir

CAS: 1009119-64-5

Purity: 98%

Molecular weight: 738.385

Ref: 10-F979825

Daclatasvir-d6

Controlled Product

CAS: 1009119-64-5

Formula: C₄₀D₆H₄₄N₈O₆

Color and Shape: Neat

Molecular weight: 744.912

Ref: TR-D101502

Daclatasvir

CAS: 1009119-64-5

Daclatasvir is a direct-acting antiviral agent, which is derived from synthetic chemical sources with a specific mode of action targeting the hepatitis C virus (HCV) replication process. It functions as an inhibitor of the HCV nonstructural protein 5A (NS5A), a vital component necessary for viral RNA replication and virion assembly. By binding to two distinct domains of NS5A, Daclatasvir disrupts its ability to function, thereby effectively halting the replication of the viral genome.

Formula: C₄₀H₅₀N₈O₆

Purity: Min. 95%

Molecular weight: 738.88 g/mol

Ref: 3D-FD158832